Results from the IMpassion 130 trial treating metastatic breast cancer from immunotherapy in cancer Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Prof Schmid speaks with ecancer at ESMO 2018 in Munich to discuss results from the IMpassion 130 trial of atezolizumab versus placebo in combinations with nab-paclitaxel to treat advanced and metastatic breast cancers.nnThe experimental combination of PD1 immunotherapy produced improvements in PFS and OS among PD-L1 positive patients, though no benefit was seen in PD-L1 negative patients. nnProf Schmid discusses the tolerability of the drug and the significance of immunotherapy entering breast c